Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age
Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age: a Point-of-care Testing Guided Randomized, Double-blind, Placebo-controlled Trial
University of Oulu
210 participants
Oct 11, 2022
INTERVENTIONAL
Conditions
Summary
The aim of the trial is to evaluate whether the use of oral prednisolone directed by point-of-care testing is useful in acute wheezing caused by rhinovirus in children aged 6-24 months.
Eligibility
Inclusion Criteria3
- Wheezing bronchitis diagnosed by a physician
- Need for salbutamol treatment at the emergency department
- Positive nasopharyngeal rhinovirus or picornavirus finding in point-of-care testing
Exclusion Criteria15
- Need for immediate resuscitation
- Immediate transfer to ICU
- Suspected pneumonia based on the auscultation finding
- Suspected serious bacterial infection
- Other respiratory virus finding in the absence of rhinovirus or picornavirus
- Positive respiratory syncytial virus finding
- Positive SARS-coronavirus-2 finding
- Positive Mycoplasma pneumoniae finding
- Positive Bordetella pertussis finding
- Contact with a person with chickenpox within 14 days
- Active chickenpox
- Suspected foreign body of the respiratory tract
- Immunosuppressive treatment
- Systemic corticosteroid treatment within 14 days
- Allergy to corticosteroids
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral suspension administered 1 mg/kg once a day for three days
Oral suspension administered the same amount in milliliters as experimental product once a day for three days
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05444699